{"id":187728,"date":"2026-08-06T10:13:35","date_gmt":"2026-08-06T04:43:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=187728"},"modified":"2026-08-06T10:13:36","modified_gmt":"2026-08-06T04:43:36","slug":"aptech-q1-results-fy27-pat-rs-7-cr","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/","title":{"rendered":"Aptech Q1 Results FY27: PAT at Rs 7 Cr for June 2026 Quarter"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Aptech Q1 results FY27: PAT Rs 7 Cr (+13.63% YoY) | Revenue Rs 133 Cr (+11.06% YoY) | Gross Margin 4.5% | Stock Rs 98.73 (up 4.95%)<\/em><\/p>\n<p>The Aptech Q1 results FY27 show consolidated revenue of Rs 133 Cr for the quarter ended 30 June 2026, +11.06% year on year from Rs 120 Cr in Q1 FY26, as <a href=\"https:\/\/univest.in\/stocks\/aptecht\/aptech-ltd-share-price-today\">Aptech<\/a> reported its numbers on 6 August 2026. Aptech posted pat of Rs 7 Cr for the quarter, against Rs 6 Cr in Q1 FY26, a change of +13.63%. Shares traded around Rs 98.73 on the NSE, up 4.95% on the day.<\/p>\n<p>The June 2026 quarter played out against a broadly stable macro backdrop, contained inflation, a supportive monsoon outlook, and resilient domestic consumption, though global uncertainty around tariffs and commodity prices kept sector-level variability elevated. Against that backdrop, the Aptech Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, gross profit, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=aptech-q1-fy27-results\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Aptech_Q1_results_FY27_Financial_Highlights\" title=\"Aptech Q1 results FY27 Financial Highlights\">Aptech Q1 results FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Aptech_Q1_results_FY27_Performance_Analysis\" title=\"Aptech Q1 results FY27 Performance Analysis\">Aptech Q1 results FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Aptech_Q1_results_FY27_Key_Business_Factors\" title=\"Aptech Q1 results FY27: Key Business Factors\">Aptech Q1 results FY27: Key Business Factors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#1_Revenue_What_Drove_the_Quarter\" title=\"1. Revenue: What Drove the Quarter\">1. Revenue: What Drove the Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#2_Gross_Profit_and_Margin_Trends\" title=\"2. Gross Profit and Margin Trends\">2. Gross Profit and Margin Trends<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#3_Net_Profit_and_Earnings_Quality\" title=\"3. Net Profit and Earnings Quality\">3. Net Profit and Earnings Quality<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Aptech_Q1_results_FY27_vs_Analyst_Expectations\" title=\"Aptech Q1 results FY27 vs Analyst Expectations\">Aptech Q1 results FY27 vs Analyst Expectations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Aptech_Dividend_Update\" title=\"Aptech Dividend Update\">Aptech Dividend Update<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Aptech_Outlook_After_Q1_results_FY27\" title=\"Aptech Outlook After Q1 results FY27\">Aptech Outlook After Q1 results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Should_You_Buy_Aptech_After_the_Q1_results_FY27\" title=\"Should You Buy Aptech After the Q1 results FY27?\">Should You Buy Aptech After the Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Aptech_Share_Price_After_the_Q1_results_FY27\" title=\"Aptech Share Price After the Q1 results FY27\">Aptech Share Price After the Q1 results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Key_Risks_to_Track_After_the_Aptech_Q1_results_FY27\" title=\"Key Risks to Track After the Aptech Q1 results FY27\">Key Risks to Track After the Aptech Q1 results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#1_Sector_and_Margin_Risk\" title=\"1. Sector and Margin Risk\">1. Sector and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#2_Single-Quarter_vs_Trend_Risk\" title=\"2. Single-Quarter vs Trend Risk\">2. Single-Quarter vs Trend Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#3_Macro_and_External_Risk\" title=\"3. Macro and External Risk\">3. Macro and External Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Frequently_Asked_Questions_on_Aptech_Q1_results_FY27\" title=\"Frequently Asked Questions on Aptech Q1 results FY27\">Frequently Asked Questions on Aptech Q1 results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#What_were_the_Aptech_Q1_results_FY27\" title=\"What were the Aptech Q1 results FY27?\">What were the Aptech Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#What_is_the_PAT_in_the_Aptech_Q1_results_FY27\" title=\"What is the PAT in the Aptech Q1 results FY27?\">What is the PAT in the Aptech Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#What_was_the_revenue_in_the_Aptech_Q1_results_FY27\" title=\"What was the revenue in the Aptech Q1 results FY27?\">What was the revenue in the Aptech Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#What_was_the_gross_profit_in_the_Aptech_Q1_results_FY27\" title=\"What was the gross profit in the Aptech Q1 results FY27?\">What was the gross profit in the Aptech Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Did_Aptech_declare_a_dividend_with_the_Q1_results_FY27\" title=\"Did Aptech declare a dividend with the Q1 results FY27?\">Did Aptech declare a dividend with the Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#What_is_the_outlook_for_Aptech_after_Q1_results_FY27\" title=\"What is the outlook for Aptech after Q1 results FY27?\">What is the outlook for Aptech after Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/aptech-q1-results-fy27-pat-rs-7-cr\/#Is_Aptech_a_good_buy_after_Q1_results_FY27\" title=\"Is Aptech a good buy after Q1 results FY27?\">Is Aptech a good buy after Q1 results FY27?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Q1_results_FY27_Financial_Highlights\"><\/span><strong>Aptech Q1 results FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>All figures are consolidated numbers in Rs Crore as reported by Aptech for Q1 FY27 (April to June 2026). The table compares them against the same quarter in FY26.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27 (Jun 2026)<\/th>\n<th>Q1 FY26 (Jun 2025)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 133 Cr<\/td>\n<td>Rs 120 Cr<\/td>\n<td>+11.06%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td>Rs 6 Cr<\/td>\n<td>Rs 5 Cr<\/td>\n<td>+29.64%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit Margin<\/td>\n<td>4.5%<\/td>\n<td>4.2%<\/td>\n<td>+0.3 pts<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (PAT)<\/td>\n<td>Rs 7 Cr<\/td>\n<td>Rs 6 Cr<\/td>\n<td>+13.63%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit Margin<\/td>\n<td>5.3%<\/td>\n<td>5.0%<\/td>\n<td>+0.3 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Q1_results_FY27_Performance_Analysis\"><\/span><strong>Aptech Q1 results FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Revenue came in at Rs 133 Cr for the June 2026 quarter, up +11.06% from Rs 120 Cr in Q1 FY26. The pace is moderate but consistent, the kind of compounding that, if sustained, translates into meaningful earnings growth over a full financial year.<\/p>\n<p>Gross profit improved faster than revenue. The gross profit came in at Rs 6 Cr (4.5% margin), up +29.64% year on year from Rs 5 Cr. The positive operating jaws confirm that Aptech is converting its topline growth into margin expansion rather than giving it away on costs.<\/p>\n<p>Aptech converted its revenue growth into earnings gains. Net profit (pat) grew +13.63% to Rs 7 Cr from Rs 6 Cr a year earlier. Consistency here over several quarters would support a valuation re-rating.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Q1_results_FY27_Key_Business_Factors\"><\/span><strong>Aptech Q1 results FY27: Key Business Factors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Revenue_What_Drove_the_Quarter\"><\/span><strong>1. Revenue: What Drove the Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aptech reported revenue of Rs 133 Cr against Rs 120 Cr in Q1 FY26, a change of +11.06%. Understanding this revenue figure requires context: in the technology sector, volume growth and realisation per unit are both drivers, and the aggregate revenue number is the product of both. Investors tracking Aptech should check the investor presentation or earnings call commentary for the volume-versus-pricing split underlying this quarter&#8217;s topline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Gross_Profit_and_Margin_Trends\"><\/span><strong>2. Gross Profit and Margin Trends<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gross margin was broadly stable at 4.5% versus 4.2% in Q1 FY26. Stability in this line is a credible outcome for the technology sector, where client spending cycles, currency movements and competitive pricing pressure can move margins sharply quarter to quarter. Sustained gross margin stability gives management a predictable base to work from as it invests in growth for the rest of FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Net_Profit_and_Earnings_Quality\"><\/span><strong>3. Net Profit and Earnings Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aptech posted pat of Rs 7 Cr for the June 2026 quarter, against Rs 6 Cr in Q1 FY26, a change of +13.63%. This bottom line figure is what drives earnings per share and, ultimately, the P\/E multiple at which the stock trades. Analysts will now update their FY27 EPS estimates using this Q1 run rate, adjusted for any seasonal factors and guidance management provides on the earnings call.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Q1_results_FY27_vs_Analyst_Expectations\"><\/span><strong>Aptech Q1 results FY27 vs Analyst Expectations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Analyst estimates for the Aptech Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 133 Cr and PAT of Rs 7 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on both revenue and profit, the stock typically sees buying in the first post-result session. A miss on both tends to trigger selling and downgrades. A mixed print stays range-bound until the earnings call provides clarity. Investors tracking Aptech should check live analyst verdict updates on the Univest Screener alongside the stock price movement to contextualise the post-result market reaction.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Dividend_Update\"><\/span><strong>Aptech Dividend Update<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No specific dividend announcement was confirmed as part of the Aptech Q1 results FY27 snapshot. Most companies declare dividends at the annual board meeting rather than with quarterly results. Investors tracking Aptech for its dividend yield should check the official NSE or BSE exchange filing, or the Univest Screener, for the latest record date and payout details.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Outlook_After_Q1_results_FY27\"><\/span><strong>Aptech Outlook After Q1 results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aptech Q1 results FY27 establish the Q1 FY27 baseline for revenue at Rs 133 Cr and PAT at Rs 7 Cr. Whether FY27 ends up as a year of acceleration depends on two variables: whether the growth in revenue sustains through Q2 to Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter&#8217;s gross profit margin of 4.5% . Management guidance on the earnings call will be the single most important datapoint for updating FY27 forecasts. Investors should also track macroeconomic inputs relevant to the technology sector through the rest of the year.<\/p>\n<p>The Q1 FY27 print gives investors a base to work from, but one quarter is rarely enough to conclude a trend. The key follow-up question for Aptech is whether the Q1 performance was driven by seasonal tailwinds or something more durable. Q2 FY27 results, due around October 2026, will be the first test of that. Investors should also watch for any corporate actions, debt announcements, or management changes in the interim.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Should_You_Buy_Aptech_After_the_Q1_results_FY27\"><\/span><strong>Should You Buy Aptech After the Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The question most investors ask after any quarterly result is whether it changes the investment case. The Aptech Q1 results FY27 show revenue of Rs 133 Cr, gross profit of Rs 6 Cr, and PAT of Rs 7 Cr. Whether these numbers justify buying, holding, or selling depends on the price the stock is trading at (Rs 98.73 at the time of this result), the FY27 consensus earnings estimate, and whether this Q1 run rate is sustainable for the remaining three quarters. Investors should check the P\/E, P\/B, and EV\/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Share_Price_After_the_Q1_results_FY27\"><\/span><strong>Aptech Share Price After the Q1 results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aptech shares traded at Rs 98.73 on the NSE, up 4.95% on the day the Aptech Q1 results FY27 were in focus. Post-result price moves are often driven by event-driven traders who have built positions ahead of the result and unwind them regardless of outcome. Investors should look past the first-session move and focus on whether the fundamental trend in revenue and earnings has changed. The 52 week high, 52 week low, and technical support levels for Aptech are available on the Univest Screener for investors who want to time their entry or exit.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aptech live share price and upcoming quarterly results.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Track_After_the_Aptech_Q1_results_FY27\"><\/span><strong>Key Risks to Track After the Aptech Q1 results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors should weigh these risks carefully before acting on the Q1 data.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Sector_and_Margin_Risk\"><\/span><strong>1. Sector and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aptech operates in the technology sector, which is exposed to client spending cycles, currency movements and competitive pricing pressure. A reversal of the trends visible in the Aptech Q1 results FY27, particularly on the gross profit margin, could put the full-year FY27 earnings estimate at risk.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Single-Quarter_vs_Trend_Risk\"><\/span><strong>2. Single-Quarter vs Trend Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A single quarterly result can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals that do not repeat. The Aptech Q1 results FY27 should be read alongside Q2 data before drawing firm conclusions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Macro_and_External_Risk\"><\/span><strong>3. Macro and External Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Macro factors including RBI rate decisions, INR\/USD movements, input commodity prices, and rural versus urban demand mix can shift the environment in the technology sector faster than company-level actions can compensate for.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aptech Q1 results FY27 show consolidated revenue of Rs 133 Cr (+11.06% year on year) and PAT of Rs 7 Cr (versus Rs 6 Cr in Q1 FY26). Gross profit came in at Rs 6 Cr at a margin of 4.5%, improving from Rs 5 Cr a year earlier. Revenue growth and a stronger bottom line were the two key themes of the quarter. Investors tracking Aptech should use the Aptech Q1 results FY27 as the baseline and watch Q2 FY27 results, due around October 2026, as the first confirmation of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Aptech_Q1_results_FY27\"><\/span><strong>Frequently Asked Questions on Aptech Q1 results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Aptech_Q1_results_FY27\"><\/span><strong>What were the Aptech Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aptech reported revenue of Rs 133 Cr (+11.06% YoY) and PAT of Rs 7 Cr for Q1 FY27 (quarter ended 30 June 2026), against Rs 6 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PAT_in_the_Aptech_Q1_results_FY27\"><\/span><strong>What is the PAT in the Aptech Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> PAT in the Aptech Q1 results FY27 stood at Rs 7 Cr, compared with Rs 6 Cr in Q1 FY26, a change of +13.63%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_revenue_in_the_Aptech_Q1_results_FY27\"><\/span><strong>What was the revenue in the Aptech Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue in the Aptech Q1 results FY27 was Rs 133 Cr, a change of +11.06% from Rs 120 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_gross_profit_in_the_Aptech_Q1_results_FY27\"><\/span><strong>What was the gross profit in the Aptech Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Gross profit in the Aptech Q1 results FY27 was Rs 6 Cr (4.5% margin), compared with Rs 5 Cr in Q1 FY26, a change of +29.64%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Aptech_declare_a_dividend_with_the_Q1_results_FY27\"><\/span><strong>Did Aptech declare a dividend with the Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was confirmed as part of the Aptech Q1 results FY27 snapshot. Check the NSE or BSE exchange filing for the latest dividend announcement from Aptech.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_for_Aptech_after_Q1_results_FY27\"><\/span><strong>What is the outlook for Aptech after Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Following the Aptech Q1 results FY27, analysts will track whether the growth in revenue and improvement in profit continue into Q2 FY27 (September quarter), along with margin trends and management guidance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Aptech_a_good_buy_after_Q1_results_FY27\"><\/span><strong>Is Aptech a good buy after Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Aptech Q1 results FY27 show revenue of Rs 133 Cr and PAT of Rs 7 Cr. Investment decisions should be based on valuation relative to earnings trajectory, not a single quarter. Consult a SEBI-registered advisor before investing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aptech Q1 results FY27: revenue Rs 133 Cr (+11.06% YoY), PAT Rs 7 Cr. Financial highlights, analysis and FY27 outlook for the June 2026 quarter.<\/p>\n","protected":false},"author":34,"featured_media":187727,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-187728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["187727"],"_edit_lock":["1785991419:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["79"],"rank_math_title":["Aptech Q1 results FY27: PAT Rs 7 Cr, Revenue Rs 133 Cr"],"rank_math_description":["Aptech Q1 results FY27: revenue Rs 133 Cr (+11.06% YoY), PAT Rs 7 Cr. Financial highlights, analysis and FY27 outlook for the June 2026 quarter."],"rank_math_focus_keyword":["Aptech Q1 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["34289"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/aptech-q1-results-fy27-pat-rs-7-cr.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/187728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=187728"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/187728\/revisions"}],"predecessor-version":[{"id":187847,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/187728\/revisions\/187847"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/187727"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=187728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=187728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=187728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}